Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice
Revista Portuguesa de Cardiologia · 2024
DOI: 10.1016/j.repc.2024.04.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Portuguesa de Cardiologia, 2024. Verfasst von Dulce Brito und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Centro Hospitalar Universitário Lisboa Norte, CAML, Lisboa, Portugal; CCUL@RISE, Faculdade de Medicina da Universidade de L…. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Hospitalization, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
INTRODUCTION AND OBJECTIVES: Heart failure (HF) is a clinical syndrome associated with substantial morbidity, mortality, and healthcare costs. Dapagliflozin has proven efficacy in reducing the risk of death and hospitalization in HF patients, regardless of left ventricular ejection fraction (LVEF). This paper aimed to project the potential impact of dapagliflozin on healthcare costs related to HF subsequent hospitalizations (HFHs) in Portuguese hospitals. METHODS: The total number of HF-related hospitalizations (hHF), HFHs, and the average length of stay for patients with a primary diagnosis of HF from six Portuguese hospitals, between January 2019 and December 2021, were collected and aggregated by hospital classification. Costs associated with HFHs were calculated according to Portuguese legislation and considering conservative, average, and complex approaches. Cost-saving projections were based on extrapolations from hHF risk reductions reported in dapagliflozin clinical trials. RESULTS: Considering a 26% risk reduction in hHF reported on pooled-analysis of DAPA-HF and DELIVER as the expected reduction in HFHs, the use of dapagliflozin would be associated with cost savings ranging from EUR 1612851.54 up to EUR 6587360.09, when considering all hospitals and the different approaches, between 2019 and 2021. A similar projection is observed based on 24% RRR derived by weighting DAPA-HF and DELIVER sub-analyses and PORTHOS epidemiological data. CONCLUSIONS: In this projection, dapagliflozin use in all eligible hHF patients is associated with a significant reduction in direct costs. Our data support that, in addition to the improvements in HF-related outcomes, dapagliflozin may have a significant economic impact on healthcare costs in Portuguese hospitals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Centro Hospitalar Universitário Lisboa Norte, CAML, Lisboa, Portugal; CCUL@RISE, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal. Electronic address: Dulce.brito@ulssm.min-sau…
- Serviço de Medicina Interna Centro Hospitalar de Lisboa Ocidental, Clínica de Insuficiência Cardíaca, Hospital de S. Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal; NOVA Medical School, Faculd…
- Serviço de Cardiologia, Unidade de Tratamento de Insuficiência Cardíaca Avançada (UTICA), Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
- Integrated Unit in Heart Failure (UNIICA), Cardiology Department, Centro Hospitalar de Setúbal, Setúbal, Portugal.
- Cardiology Department, Unidade Local de Saúde Entre o Douro e Vouga, Santa Maria da Feira, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal; University of Coimbra, Center for Innovative Biomedicin…
- Department of Internal Medicine, Unidade Local de Saúde Entre o Douro e Vouga, Santa Maria da Feira, Portugal.
Förderung
- AstraZeneca
Zitieren
APA
Brito, D., Fonseca, C., Franco, F., Lopes, V., Gonçalves, S., Baptista, R., Sequeira, J., Marques, I., Rego, R., Pimenta, J., Silva-Cardoso, J., Lopes, M., & Almeida, M. (2024). Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice. Revista Portuguesa de Cardiologia. https://doi.org/10.1016/j.repc.2024.04.012
Vancouver
Brito D, Fonseca C, Franco F, Lopes V, Gonçalves S, Baptista R, et al. Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice. Revista Portuguesa de Cardiologia. 2024. doi:10.1016/j.repc.2024.04.012
BibTeX
@article{Brito2024,
author = {Brito, Dulce and Fonseca, Cândida and Franco, Fátima and Lopes, Vanessa and Gonçalves, Sara and Baptista, Rui and Sequeira, Joana and Marques, Irene and Rego, Rita and Pimenta, Joana and Silva-Cardoso, José and Lopes, Margarida and Almeida, Mário},
title = {Beyond clinical trials – The cost saving associated with dapagliflozin use in Portugal hospital clinical practice},
journal = {Revista Portuguesa de Cardiologia},
year = {2024},
doi = {10.1016/j.repc.2024.04.012}
}
EUVIMED